

HR for cancer mortality from weighted models

GM-UAW Cohort Study

January 12, 2021

Four analyses

1. Usual mortality models (FU over 1941–1999)
2. Restricted to those still alive in 1985 (FU over 1985–1999)
3. Restricted to those still alive in 1985, weighted by probability of not dying of natural causes (FU over 1985–1999)
4. Restricted to those still alive in 1985, weighted by stabilized inverse probability with truncation at the 99th percentile of weights (FU over 1985–1999)

Stabilized weight

$$sw_i = \frac{1 - \bar{p}}{1 - \hat{p}_i}$$

where \hat{p}_i is the i^{th} individual's predicted probability of surviving to year 1985, and \bar{p} is the overall survival proportion i.e. $\frac{1}{n} \sum_i^n \hat{p}_i$.

Cox PH Models

- ▶ Outcomes: Lung cancer, stomach cancer, prostate cancer, and non-Hodgkin lymphoma
- ▶ Cumulative exposure to straight, soluble, and synthetic MWFs (lagged 21, 10, and 5 years)
- ▶ Covariates
 - ▶ Categorical calendar year
 - ▶ Categorical year of hire
 - ▶ Race
 - ▶ Sex (when possible)
 - ▶ Plant
- ▶ Risk sets indexed by age

Lung cancer (straight MWF, FU through 1999)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Lag 21										
0	648			360						
> 0 to 2	333	0.94	(0.79, 1.11)	222	0.79	(0.64, 0.98)	0.77	(0.62, 0.95)	0.78	(0.63, 0.97)
> 2	150	0.96	(0.79, 1.17)	112	0.86	(0.68, 1.09)	0.85	(0.67, 1.09)	0.85	(0.67, 1.08)
Lag 10										
0	507			301						
> 0 to 2	410	0.98	(0.83, 1.15)	258	0.91	(0.74, 1.11)	0.88	(0.72, 1.09)	0.88	(0.72, 1.09)
> 2	214	1.06	(0.89, 1.27)	135	0.92	(0.74, 1.15)	0.92	(0.73, 1.15)	0.92	(0.73, 1.15)
Lag 5										
0	487			297						
> 0 to 2	417	0.96	(0.82, 1.13)	256	0.87	(0.71, 1.06)	0.85	(0.69, 1.04)	0.85	(0.69, 1.04)
> 2	227	1.05	(0.88, 1.25)	141	0.92	(0.74, 1.15)	0.92	(0.74, 1.16)	0.92	(0.74, 1.15)

Lung cancer (exposure lagged 21 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	648			360						
> 0 to 2	333	0.94	(0.79, 1.11)	222	0.79	(0.64, 0.98)	0.77	(0.62, 0.95)	0.78	(0.63, 0.97)
> 2	150	0.96	(0.79, 1.17)	112	0.86	(0.68, 1.09)	0.85	(0.67, 1.09)	0.85	(0.67, 1.08)
Soluble										
0 to 0.05	339			139						
> 0.05 to 4	264	0.88	(0.73, 1.07)	164	0.99	(0.77, 1.26)	0.96	(0.75, 1.22)	0.99	(0.77, 1.27)
> 4 to 12.6	264	0.84	(0.69, 1.02)	187	1.11	(0.85, 1.44)	1.11	(0.86, 1.45)	1.14	(0.87, 1.49)
> 12.6	264	0.93	(0.75, 1.14)	204	1.11	(0.85, 1.45)	1.10	(0.84, 1.45)	1.10	(0.83, 1.44)
Synthetic										
0	884			509						
> 0 to 0.4	83	1.00	(0.77, 1.29)	58	1.03	(0.75, 1.40)	1.02	(0.74, 1.40)	1.01	(0.73, 1.40)
> 0.4 to 1.5	82	1.20	(0.92, 1.57)	58	1.26	(0.91, 1.74)	1.26	(0.91, 1.74)	1.27	(0.92, 1.76)
> 1.5	82	0.95	(0.74, 1.22)	69	0.95	(0.71, 1.25)	0.93	(0.70, 1.24)	0.96	(0.72, 1.27)

Lung cancer (exposure lagged 10 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	507			301						
> 0 to 2	410	0.98	(0.83, 1.15)	258	0.91	(0.74, 1.11)	0.88	(0.72, 1.09)	0.88	(0.72, 1.09)
> 2	214	1.06	(0.89, 1.27)	135	0.92	(0.74, 1.15)	0.92	(0.73, 1.15)	0.92	(0.73, 1.15)
Soluble										
0 to 0.05	172			91						
> 0.05 to 4.8	320	0.80	(0.65, 0.98)	204	0.79	(0.61, 1.03)	0.76	(0.58, 0.98)	0.81	(0.62, 1.06)
> 4.8 to 15.3	319	0.84	(0.68, 1.03)	194	0.89	(0.68, 1.16)	0.85	(0.65, 1.12)	0.91	(0.69, 1.20)
> 15.3	320	0.89	(0.72, 1.11)	205	0.93	(0.71, 1.22)	0.89	(0.68, 1.18)	0.92	(0.69, 1.22)
Synthetic										
0	794			463						
> 0 to 0.4	113	1.07	(0.85, 1.35)	76	1.09	(0.82, 1.45)	1.11	(0.83, 1.48)	1.10	(0.82, 1.49)
> 0.4 to 1.4	112	1.21	(0.96, 1.53)	71	1.24	(0.93, 1.66)	1.25	(0.92, 1.68)	1.27	(0.94, 1.70)
> 1.4	112	0.82	(0.66, 1.03)	84	0.92	(0.70, 1.19)	0.91	(0.70, 1.19)	0.92	(0.70, 1.20)

Lung cancer (exposure lagged 5 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	487			297						
> 0 to 2	417	0.96	(0.82, 1.13)	256	0.87	(0.71, 1.06)	0.85	(0.69, 1.04)	0.85	(0.69, 1.04)
> 2	227	1.05	(0.88, 1.25)	141	0.92	(0.74, 1.15)	0.92	(0.74, 1.16)	0.92	(0.74, 1.15)
Soluble										
0 to 0.05	142			82						
> 0.05 to 4.9	330	0.80	(0.65, 0.99)	213	0.86	(0.66, 1.13)	0.83	(0.64, 1.09)	0.82	(0.62, 1.08)
> 4.9 to 16.1	329	0.78	(0.63, 0.97)	202	0.89	(0.67, 1.17)	0.85	(0.64, 1.12)	0.86	(0.64, 1.14)
> 16.1	330	0.87	(0.70, 1.09)	197	0.93	(0.70, 1.24)	0.90	(0.67, 1.19)	0.87	(0.65, 1.16)
Synthetic										
0	779			455						
> 0 to 0.4	118	1.00	(0.80, 1.25)	77	1.05	(0.79, 1.40)	1.04	(0.78, 1.38)	0.99	(0.74, 1.32)
> 0.4 to 1.6	117	1.14	(0.91, 1.44)	79	1.31	(0.99, 1.75)	1.33	(1.00, 1.78)	1.35	(1.01, 1.82)
> 1.6	117	0.83	(0.67, 1.03)	83	0.93	(0.71, 1.21)	0.93	(0.71, 1.21)	0.92	(0.71, 1.21)

Stomach cancer (straight MWF, FU through 1999)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Lag 21										
0	78			29						
> 0 to 2	28	0.84	(0.48, 1.46)	17	0.97	(0.45, 2.09)	0.80	(0.36, 1.74)	0.93	(0.41, 2.08)
> 2	18	1.31	(0.77, 2.24)	11	1.27	(0.61, 2.61)	1.20	(0.58, 2.50)	1.37	(0.66, 2.86)
Lag 10										
0	55			22						
> 0 to 2	43	1.17	(0.71, 1.93)	22	1.40	(0.68, 2.92)	1.32	(0.62, 2.83)	1.40	(0.65, 3.03)
> 2	26	1.53	(0.93, 2.51)	13	1.51	(0.72, 3.18)	1.53	(0.71, 3.31)	1.66	(0.77, 3.55)
Lag 5										
0	51			21						
> 0 to 2	47	1.24	(0.77, 1.98)	23	1.49	(0.73, 3.05)	1.42	(0.68, 3.00)	1.45	(0.69, 3.03)
> 2	26	1.39	(0.86, 2.26)	13	1.50	(0.72, 3.15)	1.52	(0.71, 3.26)	1.62	(0.77, 3.44)

Stomach cancer (exposure lagged 21 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	78			29						
> 0 to 2	28	0.84	(0.48, 1.46)	17	0.97	(0.45, 2.09)	0.80	(0.36, 1.74)	0.93	(0.41, 2.08)
> 2	18	1.31	(0.77, 2.24)	11	1.27	(0.61, 2.61)	1.20	(0.58, 2.50)	1.37	(0.66, 2.86)
Soluble										
0 to 0.05	48			15						
> 0.05 to 4.4	25	0.60	(0.35, 1.04)	5	0.22	(0.08, 0.64)	0.22	(0.07, 0.66)	0.25	(0.08, 0.74)
> 4.4 to 9.3	25	0.95	(0.54, 1.67)	16	1.11	(0.48, 2.58)	1.16	(0.49, 2.72)	1.14	(0.47, 2.74)
> 9.3	26	0.47	(0.27, 0.82)	21	0.60	(0.28, 1.31)	0.59	(0.27, 1.27)	0.63	(0.28, 1.44)
Synthetic										
0	105			44						
> 0 to 0.3	10	1.44	(0.68, 3.05)	5	1.24	(0.43, 3.55)	1.10	(0.36, 3.29)	1.05	(0.34, 3.24)
> 0.3	9	0.60	(0.27, 1.34)	8	0.63	(0.24, 1.66)	0.66	(0.26, 1.70)	0.64	(0.24, 1.71)

Stomach cancer (exposure lagged 10 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	55			22						
> 0 to 2	43	1.17	(0.71, 1.93)	22	1.40	(0.68, 2.92)	1.32	(0.62, 2.83)	1.40	(0.65, 3.03)
> 2	26	1.53	(0.93, 2.51)	13	1.51	(0.72, 3.18)	1.53	(0.71, 3.31)	1.66	(0.77, 3.55)
Soluble										
0 to 0.05	21			9						
> 0.05 to 5.1	33	0.68	(0.37, 1.24)	12	0.41	(0.16, 1.07)	0.47	(0.17, 1.27)	0.50	(0.18, 1.40)
> 5.1 to 12.5	35	0.97	(0.53, 1.77)	17	0.96	(0.38, 2.41)	0.98	(0.38, 2.51)	1.04	(0.39, 2.81)
> 12.5	35	0.59	(0.32, 1.10)	19	0.60	(0.24, 1.48)	0.60	(0.24, 1.54)	0.66	(0.25, 1.78)
Synthetic										
0	96			42						
> 0 to 0.3	14	1.24	(0.65, 2.38)	7	1.09	(0.40, 2.97)	0.86	(0.30, 2.52)	0.97	(0.34, 2.75)
> 0.3	14	0.46	(0.24, 0.88)	8	0.41	(0.16, 1.03)	0.38	(0.15, 0.97)	0.41	(0.16, 1.05)

Stomach cancer (exposure lagged 5 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	51			21						
> 0 to 2	47	1.24	(0.77, 1.98)	23	1.49	(0.73, 3.05)	1.42	(0.68, 3.00)	1.45	(0.69, 3.03)
> 2	26	1.39	(0.86, 2.26)	13	1.50	(0.72, 3.15)	1.52	(0.71, 3.26)	1.62	(0.77, 3.44)
Soluble										
0 to 0.05	15			9						
> 0.05 to 5.2	34	0.71	(0.37, 1.34)	13	0.37	(0.14, 0.92)	0.41	(0.16, 1.06)	0.40	(0.16, 1.01)
> 5.2 to 13.4	37	0.95	(0.50, 1.81)	16	0.73	(0.30, 1.80)	0.71	(0.28, 1.77)	0.73	(0.29, 1.84)
> 13.4	38	0.65	(0.34, 1.26)	19	0.54	(0.22, 1.31)	0.54	(0.22, 1.34)	0.56	(0.22, 1.39)
Synthetic										
0	94			41						
> 0 to 0.4	15	0.91	(0.48, 1.72)	9	1.06	(0.43, 2.62)	0.85	(0.33, 2.24)	0.93	(0.36, 2.40)
> 0.4	15	0.46	(0.24, 0.88)	7	0.39	(0.15, 1.01)	0.37	(0.14, 0.98)	0.39	(0.15, 1.03)

Prostate cancer (straight MWF, FU through 1999)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Lag 21										
0	116			77						
> 0 to 2	75	1.08	(0.75, 1.57)	58	0.95	(0.62, 1.44)	0.98	(0.64, 1.51)	0.92	(0.60, 1.41)
> 2	42	1.20	(0.81, 1.78)	33	1.07	(0.69, 1.65)	1.10	(0.70, 1.72)	1.05	(0.67, 1.63)
Lag 10										
0	103			75						
> 0 to 2	79	0.94	(0.66, 1.34)	57	0.83	(0.55, 1.26)	0.81	(0.53, 1.24)	0.82	(0.54, 1.25)
> 2	51	1.10	(0.76, 1.58)	36	0.93	(0.61, 1.41)	0.92	(0.60, 1.41)	0.90	(0.59, 1.38)
Lag 5										
0	100			75						
> 0 to 2	81	0.95	(0.67, 1.35)	57	0.81	(0.54, 1.22)	0.78	(0.51, 1.19)	0.79	(0.52, 1.21)
> 2	52	1.10	(0.77, 1.57)	36	0.90	(0.60, 1.36)	0.89	(0.59, 1.36)	0.88	(0.58, 1.33)

Prostate cancer (exposure lagged 21 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	n	HR	95% CI	n	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	116			77						
> 0 to 2	75	1.08	(0.75, 1.57)	58	0.95	(0.62, 1.44)	0.98	(0.64, 1.51)	0.92	(0.60, 1.41)
> 2	42	1.20	(0.81, 1.78)	33	1.07	(0.69, 1.65)	1.10	(0.70, 1.72)	1.05	(0.67, 1.63)
Soluble										
0 to 0.05	50			26						
> 0.05 to 6	61	0.65	(0.43, 0.98)	44	0.64	(0.38, 1.08)	0.63	(0.37, 1.07)	0.62	(0.37, 1.06)
> 6 to 17.5	61	0.65	(0.42, 1.00)	49	0.66	(0.39, 1.12)	0.65	(0.38, 1.09)	0.65	(0.38, 1.11)
> 17.5	61	0.72	(0.45, 1.14)	49	0.66	(0.38, 1.14)	0.67	(0.39, 1.18)	0.66	(0.38, 1.14)
Synthetic										
0	174			116						
> 0 to 1.5	30	1.11	(0.67, 1.82)	26	1.43	(0.81, 2.55)	1.41	(0.77, 2.56)	1.42	(0.79, 2.56)
> 1.5	29	1.74	(1.09, 2.76)	26	1.90	(1.13, 3.22)	1.85	(1.08, 3.18)	1.88	(1.10, 3.22)

Prostate cancer (exposure lagged 10 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	103			75						
> 0 to 2	79	0.94	(0.66, 1.34)	57	0.83	(0.55, 1.26)	0.81	(0.53, 1.24)	0.82	(0.54, 1.25)
> 2	51	1.10	(0.76, 1.58)	36	0.93	(0.61, 1.41)	0.92	(0.60, 1.41)	0.90	(0.59, 1.38)
Soluble										
0 to 0.05	29			20						
> 0.05 to 7	68	0.63	(0.40, 0.99)	46	0.59	(0.34, 1.01)	0.58	(0.34, 1.00)	0.57	(0.33, 0.99)
> 7 to 19.7	68	0.65	(0.40, 1.04)	54	0.72	(0.42, 1.25)	0.72	(0.41, 1.25)	0.71	(0.40, 1.24)
> 19.7	68	0.66	(0.41, 1.07)	48	0.62	(0.36, 1.08)	0.64	(0.37, 1.11)	0.63	(0.36, 1.09)
Synthetic										
0	161			111						
> 0 to 0.6	24	1.40	(0.81, 2.42)	17	1.55	(0.79, 3.03)	1.76	(0.87, 3.55)	1.56	(0.79, 3.09)
> 0.6 to 2.2	24	1.31	(0.78, 2.21)	20	1.57	(0.85, 2.91)	1.54	(0.81, 2.93)	1.48	(0.79, 2.79)
> 2.2	24	1.60	(1.00, 2.58)	20	1.77	(1.04, 3.03)	1.72	(0.99, 2.99)	1.70	(0.98, 2.95)

Prostate cancer (exposure lagged 5 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	100			75						
> 0 to 2	81	0.95	(0.67, 1.35)	57	0.81	(0.54, 1.22)	0.78	(0.51, 1.19)	0.79	(0.52, 1.21)
> 2	52	1.10	(0.77, 1.57)	36	0.90	(0.60, 1.36)	0.89	(0.59, 1.36)	0.88	(0.58, 1.33)
Soluble										
0 to 0.05	26			19						
> 0.05 to 7.1	69	0.63	(0.39, 1.00)	47	0.61	(0.35, 1.05)	0.61	(0.35, 1.05)	0.59	(0.34, 1.02)
> 7.1 to 19.2	69	0.67	(0.41, 1.07)	53	0.76	(0.43, 1.32)	0.77	(0.44, 1.35)	0.73	(0.41, 1.28)
> 19.2	69	0.62	(0.38, 1.00)	49	0.63	(0.36, 1.09)	0.64	(0.36, 1.11)	0.63	(0.36, 1.10)
Synthetic										
0	159			110						
> 0 to 0.6	25	1.44	(0.83, 2.48)	18	1.67	(0.86, 3.24)	1.96	(0.98, 3.90)	1.68	(0.85, 3.29)
> 0.6 to 2.1	24	1.29	(0.77, 2.18)	19	1.57	(0.84, 2.92)	1.54	(0.80, 2.95)	1.47	(0.77, 2.79)
> 2.1	25	1.52	(0.95, 2.44)	21	1.76	(1.03, 3.00)	1.71	(0.99, 2.98)	1.68	(0.97, 2.91)

Non-Hodgkin lymphoma (straight MWF, FU through 1999)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	n	HR	95% CI	n	HR	95% CI	HR	95% CI	HR	95% CI
Lag 21										
0	43			23						
> 0 to 2	33	1.11	(0.59, 2.08)	24	1.50	(0.72, 3.10)	1.60	(0.76, 3.36)	1.51	(0.73, 3.16)
> 2	14	1.06	(0.54, 2.11)	11	1.35	(0.60, 3.05)	1.41	(0.62, 3.20)	1.37	(0.60, 3.10)
Lag 10										
0	39			22						
> 0 to 2	30	0.83	(0.45, 1.53)	20	0.92	(0.45, 1.90)	0.93	(0.44, 1.94)	0.94	(0.45, 1.94)
> 2	21	1.15	(0.66, 2.00)	16	1.37	(0.70, 2.68)	1.41	(0.72, 2.77)	1.38	(0.71, 2.71)
Lag 5										
0	39			22						
> 0 to 2	29	0.75	(0.42, 1.36)	20	0.94	(0.46, 1.89)	0.94	(0.46, 1.92)	0.94	(0.46, 1.91)
> 2	22	1.07	(0.63, 1.84)	16	1.31	(0.68, 2.54)	1.34	(0.69, 2.61)	1.31	(0.68, 2.55)

Non-Hodgkin lymphoma (exposure lagged 21 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	43			23						
> 0 to 2	33	1.11	(0.59, 2.08)	24	1.50	(0.72, 3.10)	1.60	(0.76, 3.36)	1.51	(0.73, 3.16)
> 2	14	1.06	(0.54, 2.11)	11	1.35	(0.60, 3.05)	1.41	(0.62, 3.20)	1.37	(0.60, 3.10)
Soluble										
0 to 0.05	17			8						
> 0.05 to 4.4	23	1.67	(0.79, 3.51)	14	1.20	(0.43, 3.34)	1.14	(0.39, 3.29)	1.34	(0.46, 3.92)
> 4.4 to 12.1	24	2.20	(0.95, 5.10)	16	1.63	(0.51, 5.21)	1.54	(0.47, 5.10)	1.79	(0.54, 6.01)
> 12.1	26	2.21	(0.90, 5.41)	20	1.55	(0.48, 4.95)	1.58	(0.48, 5.16)	1.68	(0.50, 5.64)
Synthetic										
0	66			41						
> 0 to 0.7	13	1.18	(0.55, 2.50)	7	0.77	(0.31, 1.92)	0.82	(0.32, 2.09)	0.77	(0.31, 1.93)
> 0.7	11	0.82	(0.39, 1.72)	10	0.84	(0.36, 1.98)	0.93	(0.39, 2.22)	0.84	(0.35, 1.98)

Non-Hodgkin lymphoma (exposure lagged 10 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	39			22						
> 0 to 2	30	0.83	(0.45, 1.53)	20	0.92	(0.45, 1.90)	0.93	(0.44, 1.94)	0.94	(0.45, 1.94)
> 2	21	1.15	(0.66, 2.00)	16	1.37	(0.70, 2.68)	1.41	(0.72, 2.77)	1.38	(0.71, 2.71)
Soluble										
0 to 0.05	9			4						
> 0.05 to 5.1	25	1.40	(0.64, 3.07)	19	1.61	(0.54, 4.83)	1.54	(0.51, 4.66)	1.85	(0.59, 5.78)
> 5.1 to 15.8	27	1.66	(0.71, 3.92)	14	1.35	(0.41, 4.50)	1.37	(0.41, 4.57)	1.51	(0.43, 5.28)
> 15.8	29	1.87	(0.80, 4.37)	21	1.89	(0.58, 6.22)	1.93	(0.59, 6.35)	2.09	(0.60, 7.26)
Synthetic										
0	63			38						
> 0 to 1.2	13	0.76	(0.37, 1.55)	9	0.72	(0.31, 1.69)	0.77	(0.33, 1.82)	0.73	(0.31, 1.72)
> 1.2	14	0.94	(0.48, 1.81)	11	1.10	(0.50, 2.43)	1.27	(0.57, 2.82)	1.10	(0.49, 2.45)

Non-Hodgkin lymphoma (exposure lagged 5 years)

	Full follow-up			1985 cohort			Weighted by surv.		St. inverse weight	
	<i>n</i>	HR	95% CI	<i>n</i>	HR	95% CI	HR	95% CI	HR	95% CI
Straight										
0	39			22						
> 0 to 2	29	0.75	(0.42, 1.36)	20	0.94	(0.46, 1.89)	0.94	(0.46, 1.92)	0.94	(0.46, 1.91)
> 2	22	1.07	(0.63, 1.84)	16	1.31	(0.68, 2.54)	1.34	(0.69, 2.61)	1.31	(0.68, 2.55)
Soluble										
0 to 0.05	7			4						
> 0.05 to 5.1	25	1.35	(0.59, 3.14)	18	1.43	(0.48, 4.26)	1.33	(0.44, 4.00)	1.41	(0.47, 4.21)
> 5.1 to 17.7	28	1.47	(0.61, 3.54)	15	1.19	(0.37, 3.90)	1.20	(0.37, 3.94)	1.18	(0.36, 3.84)
> 17.7	30	1.98	(0.83, 4.73)	21	1.97	(0.61, 6.42)	1.98	(0.61, 6.43)	1.92	(0.59, 6.23)
Synthetic										
0	63			38						
> 0 to 1.2	13	0.70	(0.34, 1.41)	9	0.68	(0.29, 1.58)	0.73	(0.31, 1.69)	0.67	(0.28, 1.57)
> 1.2	14	0.84	(0.44, 1.59)	11	1.01	(0.47, 2.19)	1.16	(0.53, 2.51)	1.01	(0.46, 2.19)